發(fā)布時(shí)間：2019-02-13 02:14

【摘要】：目的針對(duì)DNA倍體及MDR1與宮頸癌新輔助化療耐藥相關(guān)性進(jìn)行研究和分析。方法選取2015年1月—2017年1月,到我院進(jìn)行治療的48例LACC患者。對(duì)所有患者采取HBP方案化療,并進(jìn)行DNA定量分析檢測(cè)。評(píng)價(jià)患者化療后的療效以及染色結(jié)果。結(jié)果經(jīng)過新輔助化療治療,有效患者(完全緩解及部分緩解)27例(56.25%),其DNA倍體異倍表達(dá)率(3.7%)明顯低于無效患者(38.10%)(P0.05),且MDR1表達(dá)量(1.09±0.47)低于無效患者(2.80±0.69),差異顯著,有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論 DNA倍體及MDR1與宮頸癌新輔助化療耐藥性有關(guān),耐藥性較高的患者,DNA倍體異倍表達(dá)率更高,且MDR1表達(dá)量更大,可以作為臨床上選擇宮頸癌新輔助化療治療方案的重要參考。
[Abstract]:Objective to study and analyze the correlation between DNA ploidy, MDR1 and neoadjuvant chemotherapeutic resistance in cervical cancer. Methods from January 2015 to January 2017, 48 patients with LACC were treated in our hospital. All patients were treated with HBP regimen chemotherapy, and DNA quantitative analysis was performed. To evaluate the curative effect and staining results after chemotherapy. Results after neoadjuvant chemotherapy, 27 cases (56.25%) were effective (complete remission and partial remission), and the rate of DNA ploidy aneuploidy (3.7%) was significantly lower than that in ineffective patients (38.10%) (P0.05). The expression of MDR1 (1.09 鹵0.47) was significantly lower than that of ineffective patients (2.80 鹵0.69) (P0.05). Conclusion DNA ploidy and MDR1 are related to neoadjuvant chemotherapeutic resistance of cervical cancer. The DNA ploidy expression rate is higher and the MDR1 expression is larger in the patients with higher chemotherapeutic resistance. It can be used as an important reference for clinical selection of neoadjuvant chemotherapy regimen for cervical cancer.
【作者單位】： 深圳市人民醫(yī)院婦科;
【分類號(hào)】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 林丹;羅新;趙麗琴;蔣惠萍;易躍雄;;液基細(xì)胞學(xué)和DNA倍體檢測(cè)篩查宮頸病變的臨床研究[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年22期

2 黃先華;劉春玲;胡錦玲;楊金華;嚴(yán)苗;;宮頸液基薄層細(xì)胞學(xué)檢查聯(lián)合DNA倍體細(xì)胞檢測(cè)篩查宮頸疾病的臨床價(jià)值[J];武漢大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年01期

3 傅小一;陳秋蘭;鮑文瓏;郭斌;陳嬌;喻t，

本文編號(hào)：2421064